Insulin resistance in muscle, liver and ß-cell represent the core pathophysiologic defects in type 2 diabetes. In addition, the ominous octet all play important roles in the development of glucose intolerance in people with type 2 diabetes. How will this new paradigm shift our understanding in the way we treat our type 2 patients? Dr. Ralph DeFronzo, professor of medicine and author of the recent Banting Lecture, “From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus,” discusses new therapies based on the pathophysiology. Join host Dr. Steven Edelman to learn more.
A New Paradigm for the Treatment of Type 2 Diabetes
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Insulin resistance in muscle, liver and ß-cell represent the core pathophysiologic defects in type 2 diabetes. In addition, the ominous octet all play important roles in the development of glucose intolerance in people with type 2 diabetes. How will this new paradigm shift our understanding in the way we treat our type 2 patients? Dr. Ralph DeFronzo, professor of medicine and author of the recent Banting Lecture, “From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus,” discusses new therapies based on the pathophysiology. Join host Dr. Steven Edelman to learn more.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
MinuteCE®
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
1.00 credits
<p>Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
<p><span data-contrast="auto" xml:lang="EN-US">NYHA FC and Finerenone Response: Clinical Trial Insights</span><span data-ccp-props='{"134245417":false,"335559739":0}'> </span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?